Pharmacological treatment and current management of peripheral artery disease
- PMID: 25908730
- DOI: 10.1161/CIRCRESAHA.114.303505
Pharmacological treatment and current management of peripheral artery disease
Abstract
Patients with peripheral artery disease (PAD) are at heightened risk of both systemic cardiovascular adverse events, as well as limb-related morbidity. The optimal management of patients with PAD requires a comprehensive treatment strategy incorporating both lifestyle changes, including smoking cessation and exercise, as well as optimal medical therapy. Pharmacological therapies for patients with PAD are targeted both at modifying broad risk factors for major adverse cardiovascular events, as well as reducing limb-related morbidity. Observational data suggest that indicated pharmacological treatments are greatly underutilized in PAD, underscoring the need for improvements in patient identification and care delivery. Ongoing trials of novel therapies in patients with PAD will further inform pharmacological strategies to reduce both systemic cardiovascular risk and limb-related morbidity.
Keywords: medical therapy; peripheral artery disease.
© 2015 American Heart Association, Inc.
Similar articles
-
The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.Dan Med J. 2012 Sep;59(9):B4514. Dan Med J. 2012. PMID: 22951205 Review.
-
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.Heart. 2015 Mar;101(5):356-62. doi: 10.1136/heartjnl-2014-306906. Epub 2015 Jan 16. Heart. 2015. PMID: 25595417 Clinical Trial.
-
Medical therapy for peripheral arterial disease.Curr Opin Cardiol. 2012 Nov;27(6):592-7. doi: 10.1097/HCO.0b013e328357428a. Curr Opin Cardiol. 2012. PMID: 23032711 Review.
-
Comprehensive medical management of peripheral arterial disease.Prog Cardiovasc Dis. 2011 Jul-Aug;54(1):2-13. doi: 10.1016/j.pcad.2011.02.004. Prog Cardiovasc Dis. 2011. PMID: 21722781 Review.
-
Medical and lifestyle management of peripheral arterial disease.J Vasc Surg. 2018 Nov;68(5):1595-1606. doi: 10.1016/j.jvs.2018.07.027. J Vasc Surg. 2018. PMID: 30360849 Review.
Cited by
-
Resolvin D2 Enhances Postischemic Revascularization While Resolving Inflammation.Circulation. 2016 Aug 30;134(9):666-680. doi: 10.1161/CIRCULATIONAHA.116.021894. Epub 2016 Aug 9. Circulation. 2016. PMID: 27507404 Free PMC article.
-
9th Asian PAD Workshop.Ann Vasc Dis. 2018 Sep 25;11(3):427-436. doi: 10.3400/avd.pad.18-01000. Ann Vasc Dis. 2018. PMID: 30402197 Free PMC article. No abstract available.
-
Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD.Curr Cardiol Rep. 2020 Jan 29;22(3):13. doi: 10.1007/s11886-020-1264-z. Curr Cardiol Rep. 2020. PMID: 31997026 Review.
-
Current and Novel Emerging Medical Therapies for Peripheral Artery Disease: A Literature Review.Adv Pharm Bull. 2023 Mar;13(2):259-268. doi: 10.34172/apb.2023.025. Epub 2022 Apr 4. Adv Pharm Bull. 2023. PMID: 37342373 Free PMC article. Review.
-
Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells).Circulation. 2017 Apr 11;135(15):1417-1428. doi: 10.1161/CIRCULATIONAHA.116.025707. Epub 2017 Feb 16. Circulation. 2017. PMID: 28209728 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical